MIMETAS
MIMETAS strives to contribute to groundbreaking therapies with unique human disease biology, revealed by robust, screenable assays in the most versatile technology platform. By combining technological strengths and expertise, they establish strong drug development partnerships with and offer services to global pharmaceutical companies to develop innovative therapies to target untreatable diseases.
Latest MIMETAS Content
Whitepaper
Transforming Cancer Drug Discovery With Comprehensive Tumor Models
This whitepaper explores groundbreaking organ-on-a-chip technology and 3D tissue modeling that is closing the translational gap in cancer drug discovery.
Product News
MIMETAS Launches Ready-To-Use 3D Adult Stem Cell Organoid Tubules
MIMETAS announces that it has launched its Adult Stem Cell (ASC)-derived tubular organoids in an assay-ready format.
Advertisement
